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Objective: We hypothesized that higher neutrophil counts are associated with an increased incidence of major adverse
cardiovascular events (MACE) in patients with clinically advanced atherosclerosis.
Methods: We prospectively studied 398 patients (233 men; median age, 69 years) with symptomatic peripheral artery
disease who were admitted to the inpatient ward of the angiology department of a tertiary care university hospital in a
cohort study. Total and differential white blood cell (WBC) counts were obtained, and patients were followed forMACE,
defined as myocardial infarction, percutaneous coronary interventions, coronary artery bypass grafting, stroke, carotid
revascularization, and death.
Results: During a median follow-up of 20 months, 140 MACE occurred in 105 patients (26%). Multivariate Cox
proportional hazards analysis was used to assess the association of differential WBC count parameters (in tertiles) with
MACE and their interrelation with traditional cardiovascular risk factors and other parameters of inflammation. Patients
with neutrophil counts>5.8 G/L (upper tertile) exhibited an increased adjusted risk for all MACE (hazards ratio [HR],
1.83; P  .017), death (HR, 3.39; P  .010), and the composite of myocardial infarction, stroke, and death (HR, 2.20;
P .012) compared with patients in the lower tertile (<4.4G/L), independently of traditional cardiovascular risk factors
and levels of high-sensitivity C-reactive protein. Only neutrophils, but not eosinophils, basophils, monocytes, lympho-
cytes, or the total WBC count showed a significant association with cardiovascular outcome.
Conclusion: In patients with peripheral artery disease, neutrophil counts in the upper tertile (>5.8 G/L) indicate a
substantially increased risk for major adverse cardiovascular events, adding to the prognostic information of traditional
atherothrombotic risk factors and other parameters of inflammation. (J Vasc Surg 2005;41:610-7.)Large observational studies have established a relation
between the development of symptomatic cardiovascular
disease or cardiovascular death and the white blood cell
(WBC) count.1-7 Furthermore, in patients with acute cor-
onary syndromes, an elevated WBC count indicates an
increased risk for short- and long-term ischemic complica-
tions and death.8-14
Leukocytes of the monocyte-macrophage lineage have
a crucial pathophysiologic role in the development of ath-
erosclerotic plaque and deposition of lipids therein. The
role of granulocytes, which account for 50% to 70% of the
total WBC count, in the atherothrombotic process seems
less clear. In most prospective cohort studies that have
provided information on differential WBC count, the num-
ber of neutrophils correlated consistently with the athero-
sclerotic load and adverse outcomes in ischemic condi-
tions.8-14,20
Patients with peripheral artery disease (PAD) fre-
quently suffer from concomitant coronary artery disease
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610and cerebrovascular atherosclerosis and therefore are at a
particularly high risk for cardiovascular complications.15 In
patients with critical limb ischemia, a higher neutrophil
count may predict limb loss within 6 months.16 Although
neutrophils are supposed to contribute to the morbidity
and mortality of patients with claudication, data on the
prognostic impact of differential WBC count, particularly
in relation to other atherothrombotic risk factors, are
largely lacking for patients with PAD.14,17
We hypothesized that higher numbers of neutrophils
are associated with an increased incidence of major adverse
cardiovascular events (MACE) in PAD patients and add to
the prognostic information of traditional atherothrombotic
risk factors. Therefore, we conducted a study to investigate
the association of parameters of differential WBC count
with a combined endpoint ofMACE, defined as myocardial
infarction, percutaneous coronary interventions, coronary
artery bypass grafting (CABG), any stroke, carotid revascu-
larization, and death in patients admitted with symptomatic
PAD. Secondary objectives were to assess the association of
differential WBC count andmortality as well as a composite
of MI, stroke, and death.
METHODS
Study design. We prospectively enrolled in a cohort
study all consecutive patients with symptomatic PAD who
were admitted to the inpatient ward of the angiology
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1, 2000 to March 1, 2001.18 Study entry criterion was a
50% stenosis in the symptomatic lower limb as deter-
mined by intra-arterial angiography, which was performed
according to current state-of-the-art protocols. Patients
with acute infections unrelated to PADwere excluded. The
study was approved by the local review board and ethics
committee, and all patients gave their written informed
consent.
Patient data. On admission, two independent observ-
ers used a standard questionnaire to record the patients=
medical history and physical examination data. Clinical
history and physical examination were evaluated with spe-
cial attention to the cardiovascular risk factors and comor-
bidities of age, sex, smoking habits, hyperlipidemia, body
mass index, arterial hypertension, diabetes mellitus, coro-
nary artery disease, history of myocardial infarction, history
of cerebrovascular events, and current medication. Data
were checked for interobserver agreement on the day the
patient was discharged. In case of discrepancies, the patient
was re-evaluated by both investigators in consensus.
The ankle-brachial index (ABI) was determined by
experienced vascular technologists according to a standard-
ized and accredited protocol. On admission, routine mea-
surement of overnight fasting blood glucose and glycated
hemoglobin A1 (HbA1c) levels was done to detect undiag-
nosed diabetes mellitus. During the hospital stay, repeat
blood pressure measurements were done to detect undiag-
nosed hypertensive patients. Current infections were ex-
cluded by clinical investigation, chest radiograph, and uri-
nalysis in all patients.
Laboratory parameters. A complete series of routine
laboratory investigations were performed, including com-
plete blood cell count, global coagulation tests, HbA1c, and
levels of fasting low-density lipoprotein (LDL) high-den-
sity lipoprotein (HDL) cholesterol, and serum creatinine.
Levels of high-sensitivity C-reactive protein (hs-CRP) were
determined as described previously in these patients.18
Automated blood cell and differential WBC counts were
performed on a Sysmex NE-8000 hematology analyzer
(TOA Medical Electronics, Kobe, Japan). Samples for
blood cell analysis were obtained in all patients on the
morning of admission, in the absence of prior exercise, and
analyzed within 1 hour. Results of automated differential
WBC counts are given in G/L (109/L). Reference values
in our laboratory are neutrophils, 2.0 to 7.5 G/L; lympho-
cytes, 1.0 to 4.0 G/L; monocytes, 0.0 to 1.2 G/L; eosin-
ophils, 0.0 to 0.4 G/L; and basophils, 0.0 to 0.1 G/L.
Study endpoints. The primary composite study end-
point was the occurrence of the first MACE, consisting of
myocardial infarction, percutaneous coronary interven-
tions, coronary artery bypass grafting (CABG), stroke, ca-
rotid revascularization (carotid stenting or carotid endar-
terectomy), and death. Secondary objectives were the
occurrence of death, and a composite of acute cardiovascu-
lar events (myocardial infarction, stroke, and death). To
avoid a referral bias, peripheral vascular events such as the
occurrence of critical limb ischemia, revascularization pro-cedures, or amputations were not considered as study end-
points, because the patients of our study cohort were
referred for the treatment of symptomatic PAD. In general,
patients with claudication were admitted when a revascu-
larization was estimated to be feasible, whereas every at-
tempt of limb salvage was made in critical limb ischemia.
Subsequent recurrence of peripheral events would have
been confounded by disease stage, the location, the nature
of the lesions, and most important, the treatment strategy,
which was not randomized.
Follow-up. Patients were clinically re-evaluated rou-
tinely at 3, 6, and 12 months after hospital discharge and
then annually until December 2002 at the outpatient ward
of our department to record any MACE. A follow-up
questionnaire was also sent to each patient during Decem-
ber 2002 to re-evaluate the occurrence of MACE during
the entire follow-up period. Information from the fol-
low-up questionnaire was validated by a review of the
original hospital discharge reports for corresponding re-
admissions due to MACE. If the follow-up questionnaire
was not returned, personal telephone contact to the pa-
tients, their relatives, or to the treating physicians was
established.
Further information was obtained by reviewing the
hospital discharge reports of any other re-admission during
the follow-up period. The performance of percutaneous
coronary interventions, CABG, carotid stenting, and ca-
rotid endarterectomy was validated by review of the origi-
nal procedure protocols. Outcome was assessed by two
independent observers who were blinded to the patients=
baseline clinical and laboratory data.
Definitions. Diabetes mellitus was defined according
to the criteria of the American Diabetes Association and
was considered to be present in all patients taking antidia-
betic medication.
Hyperlipidemia was defined as fasting total serum cho-
lesterol 200 mg/dL, LDL cholesterol 130mg/dL, or
serum triglycerides180mg/dL and was considered to be
present in all patients receiving lipid-lowering therapy
(HMG-CoA reductase inhibitors [statins] were used rou-
tinely at our institution during the study period).
Arterial hypertension was diagnosed in patients with
repeated blood pressure measurements 140/90 mm Hg
and was assumed to be present in patients with a history of
hypertension who were taking antihypertensive drugs.
We recorded patients= current smoking status in four
categories: as non-smokers, patients smoking 10 ciga-
rettes/day, 11 to 20 cigarettes/day, and 20 cigarettes/
day.
For categorization of PAD, the Fontaine classification
was applied. Symptomatic PAD was defined as intermittent
claudication and critical limb ischemia. The latter included
ischemic rest pain, ulceration, and gangrene.15
Coronary artery disease was categorized according to
the Canadian Cardiovascular Society (CCS) classifica-
tion,19 and routine evaluation in symptomatic patients
included treadmill exercise testing, dobutamine echocardi-
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phy in selected cases.
Myocardial infarction was defined according to the
consensus document of The Joint European Society of
Cardiology/American College of Cardiology Committee
for the Redefinition of Myocardial Infarction20 as a tran-
sient increase of laboratory markers specific of myocardial
necrosis (CK-MB, or troponin T) along with ischemic
symptoms, typical electrocardiographic signs such as the
development of pathologic Q waves or ST segment eleva-
tion or depression, or both.
A stroke was defined as a neurologic deficit that per-
sisted24 hours. It was defined as minor if graded 1 to 2 or
major if graded 3 to 5 on the modified Rankin stroke
scale21 by a neurologist. Mandatory cranial computed to-
mography or magnetic resonance imaging, if available,
were used for confirmation of the diagnosis.
Statistical analysis. Continuous data are presented as
the median and the interquartile range (IQR, range from
the 25th to the 75th percentile). Discrete data are given as
counts and percentages. We used 2 tests to compare
proportions and Mann-Whitney U tests, or Kruskal-Wallis
tests, as appropriate, for univariate comparison of continu-
ous data. The Spearman correlation coefficient was calcu-
lated for the comparison of two continuous data sets.
Event-free survival rates until the first MACE according to
patients= baseline differential WBC count (in tertiles) are
presented as Kaplan-Meier curves and compared by means
of the log-rank test. Multivariate Cox proportional hazards
analysis was applied to assess the effect of differential WBC
counts on event free survival.
Baseline variables were entered as possible predictor
variables into the model to adjust for confounding ef-
fects if they were imbalanced between patients with
differential WBC count parameters in the upper tertile
compared with patients in the middle and lower tertile,
indicated by P  0.2, or were established risk factors for
cardiovascular events. We tested for interactions be-
tween baseline variables by stratification as well as mul-
tiplicative interaction terms and log likelihood 2 tests.
Results of the Cox proportional hazards model were
presented as the hazard ratio (HR) and the 95% confidence
interval (95% CI). A two sided P  0.05 was considered
statistically significant. Calculations were performed with
the Statistical Package for the Social Sciences (SPSS) ver-
sion 10.0 software for Windows (SPSS Inc, Chicago, Ill)
and Stata (release 8) (StataCorp, College Station, Tex).
RESULTS
Patients. We studied 398 (85%) of 467 patients who
were admitted with symptomatic PAD during the study
period. Sixty-nine patients (15%) had to be excluded owing
to missing data. Data on differential WBC count or fol-
low-up were lacking in 56 (12%) and 13 (3%) patients,
respectively. These patients with missing data closely re-
sembled the patients with complete data with respect to
clinical characteristics, without significant differences (data
not shown). The median age of the 398 patients who wereeligible for the final analysis was 69 years (IQR, 59 to 76),
233 patients were men (59%), and the median ABI was
0.58 (IQR, 0.44 to 0.73). Four (1%) of 32 (8%) patients
with ischemic rest pain were admitted for an acute throm-
botic event and 12 (3%) of 57 (14%) patients with ischemic
ulcers presented with local signs of infection.
WBC counts. The median total leukocyte count was
7.5 G/L (IQR, 6.2 to 9.0), consisting of median counts of
5.1 G/L for neutrophils (IQR, 3.9 to 6.3), 1.7 G/L for
lymphocytes (IQR, 1.3 to 2.2), 0.4 G/L for monocytes
(IQR, 0.3 to 0.5), 0.2 G/L for eosinophils (IQR, 0.1 to
0.3), and 0.1 G/L for basophils (IQR, 0 to 0.1).
Demographic data and clinical characteristics of the
398 patients according to the neutrophil count (comparing
patients in the upper tertile vs patients in the middle and
lower tertile) are presented in Table I. Patients with higher
numbers of neutrophils were younger, had hyperlipidemia
and statin therapy less frequently, and tended to have a
higher frequency of diabetes mellitus (Table I).
Current smokers exhibited significantly higher neutro-
phil counts compared with nonsmokers, depending on the
quantity of daily cigarette consumption.Median neutrophil
counts in nonsmokers, smokers of 10 cigarettes/day, 11
to 20 cigarettes/day, and 20 cigarettes/day were 4.7
G/L (IQR, 3.8 to 5.8), 4.7 G/L (IQR, 3.7 to 6.2), 5.5
G/L (IRQ, 4.8 to 6.5), and 5.7 G/L (IQR, 4.4 to 7.1),
respectively (P  .001).
Neutrophil counts showed no significant correlation
with the Fontaine stage of PAD (P  .36) or the ABI (r 
0.074, P  .23).
Median hs-CRP levels were 0.40mg/dL (IQR, 0.17 to
0.86) in these patients. Neutrophil counts were signifi-
cantly, but weakly, associated with hs-CRP (r  0.36, P 
.001), indicating that one parameter accounted for approx-
imately 13% of the variation of the other.
Follow-up for MACE. During the median follow-up
period of 20months (IQR, 12 to 25), 140MACEoccurred
in 105 patients (26%), with 14 myocardial infarctions, 39
percutaneous coronary interventions, 5 CABG procedures,
15 carotid artery stenting procedures, 5 carotid endarter-
ectomies, 21 strokes, and 41 deaths. In 35 of 105 patients,
a second endpoint occurred. For all analyses of event-free
survival, the time interval until the first MACE in each
patient was included.
Differential WBC counts andMACE. Analyzing the
specific parameters of the differential WBC count with
respect to differences of the cumulative frequency of events,
we found that neutrophil counts were significantly associ-
ated with the study endpoints. Patients in the upper tertile
of neutrophil counts (5.8 G/L) had an increased risk for
MACE and death compared with patients in the lower and
middle tertile (Fig 1). Similarly, increasing neutrophil
counts were associated with an increased risk for mortality
(P  .0010 by log rank) and the composite of myocardial
infarction, stroke and death (P .0017 by log rank). Total
WBC count (P  .22), eosinophils (P  .21), basophils (P
 .82), and monocytes (P  .58) showed no significant
association with cardiovascular outcome in these patients
(rang
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trend (P  .065) toward a better cardiovascular outcome
(Fig 2).
Being aware of several possible confounding factors, we
used a multivariate Cox proportional hazards model to
assess the association of neutrophil counts (in tertiles) with
MACE, adjusting for age (in tertiles), hyperlipidemia,
smoking, arterial hypertension, diabetes mellitus, critical
limb ischemia, history of myocardial infarction, history of
stroke, and statin therapy (Table II). Further adjustment
for the quantity of daily cigarette consumption (in four
categories) did not cause a significant effect modification,
and applying an interaction term neutrophil count*daily
cigarette consumption did not reveal a significant interaction
between these variables, indicating that neutrophil counts
were associated with the study endpoints independently of
the current smoking status.
We further analyzed potential interactions among use
of statins, hyperlipidemia, neutrophil counts, and MACE
without detecting any relevant effect modifications (log
likelihood ratio tests P  .2). Patients with neutrophil
counts 5.8 G/L (upper tertile) exhibited a 1.83-fold
increased adjusted risk (95% CI, 1.12 to 3.00; P  .017)
for MACE compared with patients in the lower tertile of
neutrophil counts (4.4 G/L). Consistently, neutrophil
counts 5.8 G/L were associated with an increased ad-
justed risk for death (adjusted HR, 3.39; 95% CI, 1.34 to
8.53; P  .010) and the composite of myocardial infarc-
tion, stroke, and death (adjusted HR, 2.20; 95% CI, 1.19
to 4.09; P  .012).
Alternatively, calculating the adjusted incremental
Table I. Demographic data, cardiovascular risk factors and
according to the baseline level of neutrophil counts (upper
Neutrophils  5
L*
(n  136, 34
Age (years) 65 (57-75)
Male sex 86 (63%)
Body mass index (kg/m2) 25.8 (23.2-28
Arterial hypertension 101 (74%)
Diabetes mellitus 62 (46%)
Smoking 77 (57%)
Hyperlipidemia 100 (74%)
Ankle-brachial index 0.56 (0.41-0.
Critical limb ischemia 36 (27%)
Coronary artery disease(CCS)
I 27 (20%)
II 26 (19%)
III 1 (1%)
IV –
History of myocardial infarction 35 (26%)
History of stroke 17 (13%)
Clopidogrel therapy 29 (21%)
Statin therapy 61 (45%)
CCS, Canadian Cardiovascular Society.
Data are given as counts and percentages or median and interquartile range
*G/L, (109/L).risk for MACE with increasing numbers of neutrophils per 1 G/L, we found a HR of 1.15 (95% CI, 1.04 to
1.27; P  .007), confirming an increasing risk with
increasing numbers of peripheral neutrophils.
Increasing numbers of atherothrombotic risk factors
(smoking, hyperlipidemia, arterial hypertension, and diabe-
tes mellitus) were associated with increasing neutrophil
counts (P  .048 by Kruskal-Wallis test). However, we
found no interaction between the number of atherothrom-
botic risk factors (0 to 1, 2, 3, and 4) and neutrophil counts
(in tertiles) bymeans of a log likelihood ratio test (P .20).
This suggests that the prognostic value of neutrophil
counts is widely independent of established atherothrom-
botic risk factors and adds to their prognostic information.
Fig 3 displays neutrophil counts in patients with and with-
out MACE according to increasing numbers of athero-
thrombotic risk factors.
To assess the interrelation of neutrophil counts with
other markers of inflammation, we additionally included
hs-CRP levels (in tertiles) in the final multivariate model
and tested for interaction between these parameters. The
overall effect size of neutrophils on MACE was slightly
attenuated by adjustment for hs-CRP (adjusted HRs, 0.94
and 1.69 for the middle and upper tertile of neutrophils
compared with the lower tertile, P  .82 and P  .043,
respectively), but there was no significant statistical inter-
action between neutrophils and hs-CRP (log likelihood
ratio 2 P  .2), indicating that neutrophils predicted
MACE independently of hs-CRP levels.
DISCUSSION
This longitudinal study supports a repeatedly described
orbidities in 398 patients with peripheral artery disease
ile vs. middle and lower tertile)
Neutrophils  5.8 G/
L*
(n  262, 66%) P
71 (60-76) 0.017
147 (56%) 0.17
25.7 (23.3-28.0) 0.95
196 (75%) 0.91
95 (36%) 0.071
94 (36%) 0.001
215 (82%) 0.047
0.59 (0.45-0.75) 0.41
53 (20%) 0.16
0.19
73 (28%)
48 (18%)
6 (2%)
–
63 (24%) 0.71
27 (10%) 0.51
68 (26%) 0.31
147 (56%) 0.033
e from the 25th to the 75th percentile).com
tert
.8 G/
%)
.6)
71)strong positive association of an elevated neutrophil count
phil c
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ischemic events4-9,14 and further confirms that observation
in patients with PAD. In these patients, neutrophil counts
in the upper tertile (5.8 G/L) indicated a substantially
increased adjusted risk for cardiovascular events during a
relatively short median follow-up period of 20 months.
This association was widely independent of traditional car-
diovascular risk factors and hs-CRP levels and thus adds to
their prognostic information.
Contrary to previous reports,1-5,7,8,10-14 we found no
significant association of the total leukocyte count with
cardiovascular outcome in our patients. This fact may rep-
resent a statistical type II error attributable to a nonsignif-
icant trend of lower lymphocyte counts towards a better
cardiovascular outcome.
Patients suffering from PAD bear a considerable risk of
myocardial infarction, stroke, or cardiovascular death that is
directly related to the severity of disease.15 The excessive
Fig 1. A, Cumulative event-free survival defined as fr
intervention, coronary artery bypass grafting, any strok
survival in 398 patients according to the baseline neutrocardiovascular event rate of 26% within 20 months in ourpatient sample confirmed that this population has to be
considered at highest risk for poor outcome and underlines
the need for additional parameters for risk stratification. An
approximately twofold increase in risk in individuals with a
single baseline neutrophil count in the top third compares
well with both the relative risks attributable to traditional
risk factors and the contribution of WBC count, as deter-
mined in large cohort studies.3,4
In our cohort, univariate comparison showed no signif-
icant association of critical leg ischemia or severity of PAD,
as indicated by ABI, with neutrophil count. In the Cardio-
vascular Health Study, statistical significance was only
found for the relation between subclinical PAD, as defined
by an asymptomatic reduction of the ABI 0.9, and WBC
count in both men and women, or clinically overt PAD in
women but not in men.22
The nature of the association of neutrophil counts with
MACE remains unclear. Despite the detailed insight into
m from myocardial infarction, percutaneous coronary
rotid revascularization and death, and (B) cumulative
ount (in tertiles).eedo
e, cathe inflammatory processes involved in the initiation, pro-
baseline eosinophils, basophils, lymphocytes and monocytes (
therapy.
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ease, it is not yet possible to determine if elevated markers
of inflammation within the normal range are a causative
factor rather than merely an indicator of cardiovascular
disease.23,24 Several epidemiologic observations have es-
tablished WBC count as a predictor of coronary heart
disease, stroke, and mortality that is independently associ-
ated with multiple coronary risk factors.1,3,4,10,25,26
Whereas leukocytes of the monocyte-macrophage lin-
eage have a crucial role in the development of atheroscle-
rotic plaque and deposition of lipids therein, the role of
granulocytes in the atherothrombotic process seems less
clear. In a French trial, a high monocyte count seemed to
predict the premature occurrence of a coronary event in
men aged 29 to 52 years.27 However, in most of the
prospective cohort studies that have provided information
on differential WBC count, the number of neutrophils
correlated primarily and consistently in a positive manner
with the atherosclerotic load and ischemic conditions.4-9,14
Acute ischemic syndromes are accompanied by markers
indicating an activation of neutrophils.28-31
In addition to the release of reactive substances such as
om myocardial infarction, percutaneous coronary inter-
vascularization and death, in 398 patients according to
in tertiles).Fig 2. Cumulative event-free survival, defined as freedom fr
vention, coronary artery bypass grafting, any stroke, carotid reTable II. Multivariate Cox proportional hazards model
to assess the association of neutrophil counts with major
cardiovascular adverse events (myocardial infarction,
percutaneous coronary intervention, coronary artery
bypass grafting, any stroke, carotid revascularization and
death) in 398 patients with atherosclerosis
Hazard
Ratio
95% Confidence
interval P
Univariate model
4.4 G/L (lower tertile) 1.0 – –
4.4-5.8 G/L (middle tertile) 1.06 0.62-1.81 0.83
5.8 G/L (upper tertile) 1.97 1.23-3.17 0.005
Model adjustments for age (in tertiles) and sex
4.4 G/L (lower tertile) 1.0 – –
4.4-5.8 G/L (middle tertile) 1.04 0.61-1.79 0.88
5.8 G/L (upper tertile) 1.99 1.23-3.20 0.005
Model adjustments for comorbidities†
4.4 G/L (lower tertile) 1.0 – –
4.4-5.8 G/L (middle tertile) 0.96 0.56-1.66 0.99
5.8 G/L (upper tertile) 1.83 1.12-3.00 0.017
*G/L, (109/L).
†Age (in tertiles), diabetes, smoking, hyperlipidemia, hypertension, critical
limb ischemia, history of stroke, history of myocardial infarction, and statinsuperoxide radicals, proteolytic enzymes, and arachidonic
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role in plaque disruption, as suggested by the direct viewing
of neutrophils invading plaque in an animal model32 or the
recent demonstration of neutrophil infiltration of culprit
lesions in acute coronary syndromes.33 Furthermore, neu-
trophils share with platelets the ability to aggregate with
either cell type or endothelial cells upon stimulation34-36;
vice versa, activation of the endothelium leads to the adher-
ence of both leukocytes and platelets. By plugging mi-
crovessels, these aggregates may contribute significantly to
the outcome in ischemic conditions.2,9,12,17,29,34
Although we can only speculate on the pathophysio-
logic significance of an elevated neutrophil count in athero-
sclerotic disease, it seems reasonable to suppose that a
higher number of circulating neutrophils will at least in-
crease the chance of their activation by altered endothelial
cells and will thereby accelerate the build-up of either
microvascular or macrovascular occlusive plugs. We there-
fore believe that our finding of an independent association
of MACE with neutrophil count only, instead of the whole
WBC count, is relevant for the prediction of MACE in
patients with PAD. In contrast to previous studies, how-
ever, we found no relation between total WBC count and
cardiovascular outcome in our patients. Presumably, this
rather unexpected finding can be explained by the statisti-
cally nonsignificant finding of a reduced event-free survival
with a lower lymphocyte count.
Study limitations. Because we included all consecu-
tive patients who were admitted to a tertiary care university
Fig 3. Neutrophil counts in patients with and without major
adverse cardiovascular events (MACE) according to the presence
of increasing numbers of the atherothrombotic risk factors of
smoking, hyperlipidemia, arterial hypertension, and diabetes mel-
litus.hospital due to symptomatic PAD, we do not believe that referral bias was a relevant issue. The positive dose-response
relationship between cigarette smoking and the WBC is
well established and complex in nature.37,38 As we did not
perform any objective measurements, such as the determi-
nation of blood cotinine, serum thiocyanate, or expired
carbon monoxide, to either confirm a nonsmoker status as
reported by our patients or quantify the smoking intensity,
we cannot rule out passive smoking, low-intensity smoking
(eg, 3 cigarettes/day), or nonreported smoking as con-
founders of our data. We also made no differentiation
between former smokers and never smokers. However, the
expected increase in leukocyte count associated with vari-
ous measures of greater smoking intensity is of small mag-
nitude and explains only a small percentage of the variance
in the WBC count.37 The relative increase of neutrophils
was shown to reach a statistically significant level only in
smokers who smoked at least one pack daily38 and might
therefore not further affect our results, which were adjusted
for the reported smoking status and derived from tertiles of
neutrophil counts.
We cannot rule out an effect of statins on WBC counts
as described previously39; however, we corrected for use of
statins in our multivariate model and did not observe any
statistical interaction between statin use, neutrophils, and
MACE, suggesting that statins did not impact the predic-
tive value of neutrophil counts.
Conclusion. Neutrophil counts in the upper tertile
(5.8 G/L) indicate an increased risk for major cardiovas-
cular adverse events in patients with PAD independently
from traditional risk factors and the level of inflammation as
measured by hs-CRP. This simple test with a wide availabil-
ity and a high interassay precision may therefore add to the
risk stratification in these patients.
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